FDA Monthly Preview: Key April Decisions to Watch - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

  • By

  • Kathryn Wighton

  • March 31, 2026

  • 3 min

Share

  • 1

    The FDA is set to make several significant regulatory decisions in April 2026 across various medical specialties.

  • 2

    GTx-104 is under review for treating aneurysmal subarachnoid hemorrhage, with a target action date of April 23, 2026.

  • 3

    AXS-05 has been accepted for priority review for Alzheimer's disease agitation, with a target action date of April 30, 2026.

  • 4

    Sparsentan's review for focal segmental glomerulosclerosis has been extended, with a target action date of April 13, 2026.

  • 5

    Teplizumab is being reviewed to expand its indication for children with stage 2 type 1 diabetes, with a target action date of April 29, 2026.

Original Source(s)

FDA Monthly Preview: Key April Decisions to Watch

  • by Kathryn Wighton

  • March 31, 2026

Related Content

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

Can external counterpulsation help early Alzheimer disease?

Researchers compared full‐pressure and low‐pressure external counterpulsation during a 12‐month trial in patients with clinically diagnosed early Alzheimer disease.